Follicular Lymphoma — Expanded Access Programs
Overview
Right2Hope maintains a directory of 42 expanded access programs, clinical trials, and compassionate use pathways listed for Follicular Lymphoma. Each entry below was sourced from sponsor disclosures and public clinical-trial registries. Use this hub to understand the breadth of ongoing research, identify sponsors with follicular lymphoma programs, and link out to specific protocols for eligibility, contact, and request details. Of these, 11 programs are currently active or recruiting, with the remaining 31 in other lifecycle stages. Sponsors actively running programs in this area include M.D. Anderson Cancer Center, Masonic Cancer Center, University of Minnesota, Reid Merryman, MD, H. Lee Moffitt Cancer Center and Research Institute, Memorial Sloan Kettering Cancer Center, and others.
By recruiting status
Snapshot of where every Follicular Lymphoma program currently sits in its lifecycle.
- Active / Recruiting11
- Inactive31
Top sponsors
Organisations running the most Follicular Lymphoma programs in the directory.
- M.D. Anderson Cancer Center3 programs
- Masonic Cancer Center, University of Minnesota3 programs
- Reid Merryman, MD3 programs
- H. Lee Moffitt Cancer Center and Research Institute2 programs
- Memorial Sloan Kettering Cancer Center2 programs
- Merck Sharp & Dohme LLC2 programs
- ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)1 program
- BeiGene1 program
- Beth Israel Deaconess Medical Center1 program
- Brown University1 program
Follicular Lymphoma programs (42)
Sorted by recruiting status, then alphabetically by program name. Click any program to view eligibility, locations, and sponsor contact details.
- Study on MK-1045 and Rituximab for Treating Follicular Lymphoma — Merck Sharp & Dohme LLC
- Long-term Study of Ibrutinib for Ongoing Access and Safety Monitoring — Janssen Research & Development, LLC
- Study on Nemtabrutinib for Patients with Difficult-to-Treat Blood Cancers — ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
- Study on Using Lower Dose Radiation Therapy for B-Cell Lymphomas — Memorial Sloan Kettering Cancer Center
- Study Comparing Golcadomide and Rituximab with Other Treatments for Relapsed or Hard-to-Treat Follicular Lymphoma — Celgene
- Study on Emapalumab to Prevent Side Effects from CAR-T Cell Therapy in Non-Hodgkin's Lymphoma Patients — Marcela V. Maus, M.D.,Ph.D.
- Study on Epcoritamab for Follicular Lymphoma Patients Not Achieving Complete Response with Initial Chemoimmunotherapy — Beth Israel Deaconess Medical Center
- Study on Epcoritamab, Zanubrutinib, and Rituximab for Treating Relapsed or Refractory Follicular Lymphoma — Reid Merryman, MD
- Phase 2 Study of Tafasitamab with Lenalidomide and Rituximab for Untreated Follicular and Marginal Zone Lymphoma — Masonic Cancer Center, University of Minnesota
- Study on Copanlisib and Rituximab for Untreated Follicular Lymphoma — National Cancer Institute (NCI)
- Study on Abexinostat for Patients with Relapsed or Hard-to-Treat Follicular Lymphoma — Xynomic Pharmaceuticals, Inc.
- Study on BGB-16673 for Patients with B-Cell Blood Cancers — BeiGene
- Study on a New Vaccine (EO2463) Alone and with Other Treatments for Indolent Non-Hodgkin Lymphoma — Enterome
- Phase II Study of Axicabtagene Ciloleucel (CAR T-Cell Therapy) with Radiation for Treating Relapsed or Hard-to-Treat Follicular Lymphoma — M.D. Anderson Cancer Center
- Study on the Safety and Effectiveness of CTX112 for Treating Difficult or Returning B-Cell Cancers — CRISPR Therapeutics AG
- Study on the Safety and Effectiveness of Mosunetuzumab and Lenalidomide for Follicular Lymphoma — Hoffmann-La Roche
- Study on Mosunetuzumab for People with Follicular Lymphoma — Memorial Sloan Kettering Cancer Center
- Study on Tazemetostat with Rituximab and Bendamustine for Initial Treatment of High Tumor Burden Follicular Lymphoma — Vaishalee Kenkre
- Study on Zilovertamab Vedotin as a Single Treatment and in Combination for Aggressive and Slow-Growing B-cell Blood Cancers — Merck Sharp & Dohme LLC
- Study on Tazemetostat with Lenalidomide and Rituximab vs. Placebo for Adults with Relapsed/Refractory Follicular Lymphoma — Epizyme, Inc.
- Study on Using Reduced Intensity Conditioning and Post-Transplant Cyclophosphamide for Blood Disorders — Masonic Cancer Center, University of Minnesota
- Study on Stem Cell Transplant Followed by Polatuzumab Vedotin for B-cell Non-Hodgkin and Hodgkin Lymphoma — New York Medical College
- Study on CAR-20/19-T Cells for Patients with Hard-to-Treat B Cell Cancers — Medical College of Wisconsin
- Study on Cytokine-Treated Veto Cells for Patients with Blood Cancers After Stem Cell Transplant — M.D. Anderson Cancer Center
- Study on Epcoritamab and Rituximab for First-time Treatment of Follicular Lymphoma — Reid Merryman, MD
- Expanded Access Study for Patients Needing Axicabtagene Ciloleucel Treatment — Kite, A Gilead Company
- Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma — Reid Merryman, MD
- Study on Lenalidomide and Epcoritamab for Treating Untreated Follicular Lymphoma — City of Hope Medical Center
- Local Production of CAR T-Cell Therapy for Treating B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia — John Lister
- Study on Loncastuximab Tesirine and Rituximab for Treating Relapsed or Hard-to-Treat Follicular Lymphoma — Juan P. Alderuccio, MD
- Study on Mosunetuzumab and Polatuzumab Vedotin for Untreated Follicular Lymphoma — Washington University School of Medicine
- Study on Mosunetuzumab and Lenalidomide as First Treatment for Follicular and Marginal Zone Lymphoma — Brown University
- Study on Myeloablative Stem Cell Transplant with Donor for Blood Disorders — Masonic Cancer Center, University of Minnesota
- Study on Odronextamab for Treating Low Tumor Volume Advanced Follicular Lymphoma — Gottfried von Keudell, MD PhD
- Study on Oncoquest-L Vaccine for Patients with Untreated Stage III or IV, Asymptomatic, Non-bulky Follicular Lymphoma — XEME Biopharma Inc.
- Study on Improving Immunity with PCV13 Vaccine Before and After CAR-T Therapy — H. Lee Moffitt Cancer Center and Research Institute
- Phase 2 Trial of Obinutuzumab and CC-99282 for Patients with Untreated High Tumor Burden Follicular Lymphoma — M.D. Anderson Cancer Center
- Study on Rituximab and Zanubrutinib for Patients with Slow-Growing B-cell Lymphomas — H. Lee Moffitt Cancer Center and Research Institute
- Safety and Effectiveness Study of Epcoritamab Combinations for B-cell Non-Hodgkin Lymphoma — Genmab
- Study of the Monoclonal Antibody IMT-009 in Patients with Advanced Solid Tumors or Lymphomas — Immunitas Therapeutics
- Tazemetostat and Mosunetuzumab in Untreated Follicular Lymphoma — Weill Medical College of Cornell University
- Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation — University of Michigan Rogel Cancer Center
About this hub
Expanded access programs (sometimes called compassionate use, named-patient programs, or pre-approval access) allow patients with serious or life-threatening conditions such as Follicular Lymphoma to receive an investigational therapy outside of a controlled clinical trial when no comparable approved option is available. Eligibility, location, and the application process differ for each program — review the individual program pages below for sponsor contact information, inclusion criteria, and the request workflow. Right2Hope is a 501(c)(3) nonprofit and provides this directory free of charge for patients, caregivers, and treating physicians.
Looking for a different condition? Browse the full Cancer Type hub directory or search the full expanded access program catalog.